The hedge fund’s shares of CHS are valued at $26.63 million. CHS makes up about 15.09 percent of Accipiter’s portfolio, according to Trade Calls.
Other hedge funds, including D. E. Shaw, also upped their stakes in CHS in the most recent quarter.
More articles on healthcare finance:
Should providers become payers? 4 key considerations
Calif. denies Saint Agnes Medical Center’s request to lower charity care minimum
AHA urges CMS to delay site-neutral payment policy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
